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ABSTRACT: In this study, the interaction of selected pharmaceutical excipients on the function of P-glycoprotein (P-gp) and activity of 6 cytochrome P450 (CYP) isoforms were computationally investigated. At binding free energy cut-off value of −5.0 kcal/mol, the result showed possible
modulatory or inhibitory effect by cethyl alcohol on CPY3A4 and P-gp; cetyltrimethyl-ammonium bromide (CTAB) on CYP1A2 and P-gp; dibutyl
sebacate on CYP2C9, CYP2E1, and P-gp; sodium caprylate on CYP1A2 and CYP3A4; while most of the tested excipients have good interaction with the cytochromes and P-gp. The predicted pharmacokinetics provided possible inhibitors of the CYPs and P-gp and suggested that
aspartame and acetyl tributyl citrate may not permeate blood–brain barrier and not act as P-gp substrates. Target prediction for CTAB showed
100% and 35% probability of target to dynamin-1 (UniProt ID: Q05193) and histamine H3 receptor (UniProt ID: Q9Y5N1), respectively, whereas
tricaprylin showed 40% probability of target to 5 Protein kinase C (UniProt IDs: P17252, Q02156, Q04759, P24723, and P05129). This study
shows that synergistic effect of some excipients present in a drug formulation and multiple drugs administration is possible through modulation
of CYPs activities and P-gp function, and this is crucial for consideration to mitigate toxicity in pediatric and adult populations.
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Introduction

According to Kolter and Guth,3 drug delivery systems often
require highly functional excipients to achieve the targeted
product properties. There are 3 types of excipients based on
development approaches: (a) modified excipients (existing
physical or purity has been changed)—examples include
Kollidon VA 64 Fine, Polyplasdone Ultra, and Tween 80 HP;
(b) coprocessed excipients (excipients are formulated to yield
new combination)—examples include Aquarius, Ludiflash
(Mannitol–Polyvinylacetate–Crospovidone), and StarCap
1500; and (c) novel excipients (chemical entities newly discovered)—examples include Captisol, Kollicoat IR, and Soluplus.
Excipients are used to bring about changes in the pharmacological activity of the drug by altering solubility, dissolution,
permeability, and bioavailability.4 Until recently, excipients
were believed to be passive with no biological activity of their
own. Changes in the transporter-mediated absorption of substrates and modulations in cytochrome P450 (CYP) enzymes
activity have been associated with excipients in several studies.4-6 Enhancement or inhibition of CYPs activities can
change drug metabolism profile and result in either increase in
the bioavailability or decrease in the efficacy of the drug.6
There are more than 55 human CYP homologues, of which
90% of therapeutic drugs are metabolized by CYP1A2,

Pharmaceutical excipients play important role in the overall
kinetics of active pharmaceutical ingredients (APIs) by influencing the activity of hepatic and intestinal metabolic enzymes
and transporters. The systemic bioavailability of API administered through oral route is often decreased by first-pass biotransformation through both hepatic and intestinal enzymes1
and may be increased through formulation with excipients that
can positively alter the enzymes and transporters responsible
for first-pass metabolism. The International Pharmaceutical
Excipients Council (IPEC) defines excipients as substances
other than the API which have been appropriately evaluated
for safety and are intentionally included in a drug delivery system. Pharmaceutical excipients are materials, excluding the
API, intentionally included in a drug product to satisfy the criteria for quality by regulatory bodies and safety of patients in
terms of manufacturability or composition, performance, and
appearance or specifications.2 According to Moreton,2 pharmaceutical excipients are a very sundry group of materials
which may exist in all the states of matter: liquid, gas, and solid
(as well as semi-solid), they can be of natural or synthetic (as
well as semi-synthetic) source and of various molecular sizes
(simple molecules or very complex polymers).
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CYP3A4, CYP3A5, CYP2C9, CYP2C19, CYP2D6, and/or
CYP2E1.7,8 The cytochrome P450 3A (CYP3A) family constitute more than 70% of small intestinal cytochrome P450 and
has CYP3A4 as the key enzyme.9
Permeability glycoprotein also known as P-glycoprotein
(P-gp; MDR1; ABCB1) is an efflux transporter which belongs
to ATP-binding cassette (ABC) superfamily of transporters,
actively transport a wide range of structurally and mechanistically diverse endogenous and xenobiotics across the cell membrane at the energy expense of ATP hydrolysis,10 and found in
blood–brain barrier (BBB), gastrointestinal tract, liver, placenta,
and kidneys in humans.4 P-gp efflux and CYPs activity can
profoundly implicate the role of drug pharmacokinetics by
clinically altering the administered drug efficacy or resulting to
various adverse side-effects due to drug–drug interactions
(DDIs), as in the case of multi-administration of drugs and
herbal formulations.10-13 Although DDIs often lead to negative impact on therapy, they can also be leveraged in drug regimens to facilitate the absorption of drugs and increase their
bioavailability.14
The manufacturing process of many excipients might contain levels of reactive impurities (such as reducing sugar, aldehydes, peroxides, nitrites, organic acids, and metals), which
might lead to incompatibilities with APIs in the formulations.15
Pharmacokinetics/toxicokinetics of excipients is the study of
absorption, distribution, metabolism, and excretion (ADME) of
excipients in relation to their pharmacological/toxic effects. The
chemical structure and chemical and physical properties of the
excipients are to be examined first in hazard identification, as
these may show possible toxicological issue.16 In pharmacological study, substrate are compounds actively transported and
metabolized by enzymes; inhibitors are compounds that prevent
transport or enzymatic activity and increase the level of substrates, whereas modulators or inducers are compounds that
interact with another binding site different from where the substrate binds on transporter or enzyme and decrease the level of
substrates (increase the bioavailability). Studies have classified
different drug compounds interaction with numbers of
cytochrome P450 (CYP) isoforms which include imipramine
(for 1A2, 2D6, 3A4), omeprazole (for 2C19, 3A), losartan (for
2C9, 3A4), and digoxin (for P-gp).1,4,17 The need to study the
potential pharmacological benefits and toxicological liabilities
of commonly used small molecule excipients is therefore becoming increasingly apparent. In this study, the pharmacokinetics
and molecular binding of 11 selected common small molecule
excipients used in drug formulation were computationally
investigated for their effect on the function of P-gp and activity
of selected cytochrome P450 isoforms.

Materials and Methods
In silico preparation of ligands
Eleven small molecule excipients were adapted from available
published literatures.4,18,19 Available structure of each of the
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compounds (ligands) was obtained from the PubChem
Compound Database in structure data file (sdf ) and canonical
SMILES (Simplified Molecular Input Line Entry
Specification) format. The ligand structures generated were
subjected to 3-dimensional optimizations using ChemSketch
and saved as mol2 format. All file conversion to protein data
bank (pdb) format were performed using PyMol v2.0.7.

In silico preparation of first-pass targets
Six cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2C9,
CYP2C19, CYP2D6, and CYP2E1) and P-gp, which are key
targets involved in first-pass effect of drug metabolism, were
selected based on the information available in published literature.1,4,6,17 The 3-dimensional (3D) structure of each of the
cytochrome p450 was obtained from RCSB Protein Data
Bank (PDB) database.

Molecular docking studies
The molecular docking studies were performed according to
the method of Fatoki et al.20 Briefly, all water molecules, hetero
atoms, and multichain were removed from the crystal structure
of the prepared targets using PyMol v2.0.7. The Gasteiger partial charges were added to the ligand atoms prior to docking.
The docking parameter of each prepared ligand and each prepared target was setup using AutoDock Tools (ADT) v1.5.6,21
and molecular docking program AutoDock Vina v1.1.222 was
employed to perform the docking experiment.

In silico pharmacokinetics and target prediction
The ligands were then subjected to in silico ADME
(Absorption, Distribution, Metabolism, and Excretion) screening on SwissADME server.23 ADME screening was performed
at default parameters. In silico prediction of target for the
excipients was done using SwissTargetPrediction server where
Homo sapiens was selected as target organism.24 The information about medications that contain each of the selected excipients used in this work was obtained from www.drugs.com.

Molecular dynamics simulation
The dynamics of P-gp structure (PDB: 6C0V, chain A) was
investigated according to the method of Ugboko et al25 at pH
7.5. Briefly, from the crystal structure (X-ray structure),
PDBFixer implemented in OpenMM v7.326 on CPU platform
was used to fix the protein. The OpenMM ForceField was
instantiated using amber14/protein.ff14SB and amber14/tip3p
water model with constraints on the lengths of all bonds
involving a hydrogen atom and TIP3P waters were added to a
cubic box extending 10 Å beyond the outermost protein atoms
with 200 mM NaCl. The energy minimization was conducted
until a tolerance of 25 kJ/mol using a Langevin integrator27
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with a time step of 2.0 fs, temperature of 300.0 K, and collision
rate of 5.0 p/s using single precision. Non-bonded forces were
modeled using the particle-mesh Ewald (PME) method28 with
a cutoff distance of 10 Å and a Monte Carlo Barostat with
pressure of 1 atm with update at interval of 50 steps. The minimized protein was then subjected to fast simulation of structural flexibility using CAB-flex 2.0 server29 with random
number generation seed of 4685 while other parameters were
at default settings. The contact map and root-mean square
fluctuations (RMSF) of amino acid residues in the server-analyzed protein were obtained.

Results and Discussion

Several studies have been done to determine how to overcome
first-pass metabolism of drug by understanding the nature of
the substrates, inhibitors, and inducers of these enzymes and
transporters as well as the influence of excipients in DDI
favorable to bioavailability of API.4,30 Eleven small molecule
excipients used in this study (and their PubChem identification number) were acetyltributyl citrate (6505), ascorbyl palmitate (54680660), aspartame (134601), cetyl alcohol (2682),
cetyltrimethyl-ammonium bromide (CTAB; 5974), dibutyl
sebacate (7986), docusate sodium (23673837), lactose monohydrate (104938), sodium caprylate (23664772), sucrose stearate (9898327), and tricaprylin (10850). The effect of selected
poly-molecule pharmaceutical excipients on cytochrome P450
(CYP) and P-gp has been studied experimentally, of which
results showed that most excipients were capable of inhibiting
and increasing activity of several different CYP isoforms as
well as inhibit P-gp transport function at therapeutic concentration.4,6 Also, pharmaceutical excipients that are surfactants
such as SLS, RH40, Tween 20, and EL35 have been found to
attenuate 2 major forms of human carboxylesterase (CES1A
and CES2) activities.31
The docking parameters and predicted active site amino
acid residues are shown in Table 1. Interaction of P-gp with
many structurally diverse compounds indicates the presence of
multiple binding sites. Two different ligand binding sites were
predicted for P-gp in this study, which are possibly for ATP
binding (nucleotide-binding domain) and xenobiotic binding
(transmembrane domain). The binding free energy between
the excipients and selected first-pass metabolic proteins is
shown in Table 2. The lesser the binding energy, the more the
possibility that the excipient will undergo first-pass effect by
the appropriate CYPs and P-gp. At binding free energy cut-off
value of −5.0 kcal/mol, the result showed possible modulatory
or inhibitory effect by cetyl alcohol on CPY3A4 and P-gp;
CTAB on CYP1A2 and P-gp; dibutyl sebacate on CYP2C9,
CYP2E1, and P-gp; sodium caprylate on CYP1A2 and
CYP3A4; while other excipients in this study have good interaction with the cytochromes and P-gp at value below −5.0 kcal/
mol, except interaction of docusate sodium with CYP2C9 and
CYP2E1 as well as ascorbyl palmitate with CYP3A4.
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Despite efforts on the prediction of P-gp inhibitors or substrates, the accuracy of the prediction models is still a serious
challenge.32 However, the molecular docking results could not
differentiate between the excipients that are substrates, inhibitors, or modulators; hence, these compounds are classified as
substrates, inhibitors, and modulators in this study. Thus, the
results of predicted pharmacokinetics (ADME) as shown in
Table 3 provided possible inhibitors of the CYPs and P-gp.
Excipients E, G, and H were not substrates for P-gp, whereas
others may be inhibitors or modulators of P-gp. Also, excipients C, E, G to J may probably be substrates for CYPs because
they were not found as inhibitors for any of cytochrome P450
curated in the SwissADME database.
Hypothetically, small molecule excipient with cumulative
binding energy (CBE) which is below –42.5 kcal/mol (such as
excipient H) is likely to have high rate of first-pass metabolism
and it is termed as CBE-A excipient, whereas small molecule
excipient with CBE which is above –42.5 kcal/mol is likely to
enter systemic circulation to exert certain level of biological
effects, and it is termed as CBE-B excipient (Table 2). Thus,
medication that contains 3 or more of CBE-B excipients
should be reformulated to yield acceptable bioequivalence such
as tramadol hydrochloride and omeprazole (Table 4). Moreover,
different brands of medications usually have different excipients composition in their formulation but achieved the same
bioequivalence. The incompatibility or interaction of excipients
with certain APIs has been reviewed by Bharate et al.33
In silico target prediction showed that 3 of the excipients
have potential target; CTAB showed 100% and 35% probability of target to Dynamin-1 (UniProt ID: Q05193) and
Histamine H3 receptor (UniProt ID: Q9Y5N1), respectively;
ascorbyl palmitate showed 65% probability of target to glycogen synthase kinase-3 beta (UniProt ID: P49841), whereas tricaprylin showed 40% probability of target to 5 Protein kinase
C (UniProt IDs: P17252, Q02156, Q04759, P24723, and
P05129).
Studies on antimalarial activity of CTAB have shown that it
interferes with Plasmodium falciparum phospholipid metabolism34,35 and choline kinase36 as well acts as inhibitor of cyclopropane mycolic acid synthase 1 (Uniprot ID: P9WPB7) in
Mycobacterium tuberculosis.37 Also, CTAB is one of the trace
components of Aflunov and Foclivia, which are vaccines for
influenza virus (Table 4).
This study therefore revealed the effects of first-pass metabolic CYPs and P-gp on the inertness of excipients of pharmaceutical, topical and food applications. Study has also shown
that nanoparticles of CTAB increase the intracellular concentrations of P-gp substrates.38 Previous in vivo study has indicated that ascorbyl palmitate did not inhibit CYP3A4 activity
though it was found to be a moderately potent reversible inhibitor of in vitro tested CYP3A4 activity.39 Thus, the level of
inhibition of CYP450 by ascorbyl palmitate as predicted in this
study (Table 3) may not indicate significant impact in an in

Center grid box
(points)

3.511 × 21.453 × 26.116
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4.165 × 23.443 × 4.859
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2HI4, chain A)

Cytochrome P450 3A4 (PDB:
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Cytochrome P450 2C9 (PDB:
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(PDB: 4GQS, chain A)

Cytochrome P450 2D6 (PDB:
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Cytochrome P450 2E1 (PDB:
3LC4, chain A)
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Asp164, Tyr401, Arg404, Ile409, Asn428, Ser429, Gly430, Cys431, Gly432, Lys433,
Ser434, Thr435, Gln475, His587, Arg905, Lys1076, Ser1077, Thr1078, Phe1157,
Gln1175, Leu1176, Ser1177, Gly1179, Gln1180

0.875

Ala529, Gln530, Ser532, Gly533, Gly534, Gly535, Tyr1044, Thr1046, Arg1047,
Val1052, Ser1071, Gly1073, Cys1074, Gly1073, Cys1074, Gly1075, Lys1076, Ser1077,
Thr1078, Gln1118, Gln1201

Arg100, Ile114, Ile115, Trp122, Arg126, Leu133, Ile180, Leu296, Ala299, Gly300,
Thr303, Thr304, Thr307, Gln358, Leu363, Val364, Asn367, Leu368, His370, Leu393,
Pro429, Phe430, Ser431, Thr432, Lys434, Arg435, Val436, Cys437, Ala438, Gly439,
Leu442, Ala443, Leu447

Arg101, Val119, Phe120, Trp128, Arg132, Ile186, Leu302, Ala305, Gly306, Thr309,
Thr310, Thr313, Gln364, Val374, His376, Leu399, Pro435, Phe436, Ser437, Ala438,
Arg441, Ala442, Cys443, Leu444, Gly445, Leu448, Ala449, Glu452

0.475

0.475

Arg97, Ile112, Val113, Trp120, Arg124, Leu131, Ile178, Leu294, Ala297, Gly298, Thr301,
Thr302, Thr305, Gln356, Ser365, Leu366, His368, Pro427, Phe428, Ser429, Ala430,
Lys432, Arg433, Ile434, Cys435, Val436, Gly437, Glu438, Leu440, Ala441, Glu444

Trp120, Arg124, Leu131, Ile178, Leu294, Ala297, Gly298, Thr301, Thr302, Thr305,
Gln356, Leu361, Ser365, Leu366, His368, Leu391, Pro427, Phe428, Ser429, Ala430,
Lys432, Arg433, Ile434, Cys435, Val436, Gly437, Leu440, Ala441, Leu445

Arg105, Ile118, Ser119, Trp126, Arg130, Phe137, Phe302, Ala305, Gly306, Thr309,
Thr310, Val313, Leu364, Ile369, Ala370, Leu373, Arg375, Pro434, Phe435, Gly436,
Arg440, Asn441, Cys442, Ile443, Gly444, Phe447, Ala448, Met452

Arg108, Thr124, Trp133, Arg137, Leu144, Ile200, Asp313, Ile314, Ala317, Gly318,
Thr321, Val322, Ala325, Phe376, Phe381, Leu382, Thr385, Ile386, His388, Gln411,
Leu450, Phe451, Gly452, Met453, Lys455, Arg456, Arg457, Cys458, Ile459, Gly460,
Leu463, Ala464, Ile468

Predicted binding site residues

0.475

0.475

0.475

0.475

Spacing (Å)

Table 1. The docking parameters for first-pass-related enzymes and predicted active site amino acid residues.
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Table 2. Docking score for the binding free energy between the first-pass metabolic proteins and selected excipients.
First-pass targets

Binding energy (kcal/mol) of the selected excipients
A

B

C

D

E

F

G

H

I

J

K

Cytochrome P450 1A2 (PDB: 2HI4)

–5.0

–5.7

–5.5

–4.5

–7.1

–4.0

–5.1

–6.8

–6.1

–6.0

–4.9

Cytochrome P450 3A4 (PDB: 1TQN)

–5.1

–4.9

–6.6

–5.8

–3.8

–4.5

–7.0

–7.4

–5.1

–6.1

–5.7

Cytochrome P450 2C9 (PDB: 5A5J)

–5.0

–6.6

–5.3

–4.2

–4.4

–5.4

–4.9

–7.3

–4.3

–5.1

–5.5

Cytochrome P450 2C19 (PDB: 4GQS)

–5.0

–5.8

–6.1

–3.9

–4.2

–4.4

–5.8

–7.7

–4.9

–6.3

–5.8

Cytochrome P450 2D6 (PDB: 4WNW)

–5.5

–5.4

–6.5

–4.0

–4.4

–4.8

–5.7

–7.0

–4.3

–5.4

–5.5

Cytochrome P450 2E1 (PDB: 3LC4)

–5.3

–5.8

–6.2

–4.7

–4.5

–6.9

–4.9

–7.8

–4.5

–5.8

–5.3

P-glycoprotein (PDB:6C0V)

–5.1

–6.9

–6.3

–5.3

–5.7

–5.1

–6.7

–8.5

–4.8

–6.7

–5.1

Cumulative binding energy

–36.0

–41.1

–42.5

–32.4

–34.1

–35.1

–40.1

–52.5

–34.0

–41.4

–37.8

Selected excipients: (A) acetyltributyl citrate, (B) ascorbyl palmitate, (C) aspartame, (D) cetyl alcohol, (E) cetyltrimethyl-ammonium bromide (CTAB), (F) dibutyl sebacate,
(G) docusate sodium, (H) lactose monohydrate, (I) sodium caprylate, (J) sucrose stearate, and (K) tricaprylin (caprylic acid triglyceride). The bold values show the lowest
and highest binding energy for the targets (across the row).

vivo pharmacological evaluation. From results of this in silico
study which showed that ATBC may not permeate BBB and
not act as P-gp substrate, it can be theorized that ATBC may
possibly act as inhibitor of P-gp and CYP2C19 in the intestinal cell, with no further systemic distribution to the liver and
brain. Investigation of acetyl tributyl citrate (ATBC) in both in
vitro and in vivo has shown increase in the CYP3A4 messenger
ribonucleic acid (mRNA) level and enzyme activity, both in the
human intestinal cells but not in liver cells.40 The P-gp mediates decrease in the availability of substrates for CYP thereby
affecting the apparent metabolic activity.17 The pharmacokinetics of a drug may be altered when formulated with excipients which inhibit or induce P-gp. The inhibition and induction
of P-gp often result in increase and decrease in bioavailability,
respectively. The high binding energy of lactose monohydrate
implicated it as good substrate for both CYPs and P-gp, thus
resulting in lower gastrointestinal absorption and lower bioavailability; this showed that the affinity of ligand to protein
target does not often connote inhibitory mode of action.
Tricaprylin is the triester of caprylic acid with glycerin and
has applications as food additive, cosmetics agent, and pharmaceutical excipient. Study has shown extensive damage of tumor
cells (lymphoma implants in the liver) in rats after oral dosing
with tricaprylin.41 Increase in the level of 7 cytochrome P450
which includes CYP2E1 and CYP1A2 in cerebrum and cerebellum microsomal fractions of rat brain has been found to be
associated with excessive amount of aspartame, whereas hepatic
microsomal fractions showed no differences in CYPs concentration and activity,42 but CYP3A2 activity was induced in the
brain and liver.43 This corroborates the result of this study
which predicted that aspartame has no inhibitory effect on the
hepatic and intestinal CYPs and P-gp, and its inability to cross
BBB suggests no induction effect on the brain CYPs and P-gp.
The expression P-gp at endothelial capillaries of the brain
aids BBB against xenobiotic access to the central nervous system.

As shown in Table 3, it could be deduced and hypothesized that
(a) for any small molecule that is BBB permeant and P-gp substrate simultaneously cannot be an inhibitor of CYPs, (b) for any
small molecule that is not BBB permeant and P-gp substrate
simultaneously or independently will be an inhibitor of 1 or
more CYPs. Simultaneous inhibition of the cytochrome or ABC
transporter in the mammal host and the target organism has
been found to enhance pharmacokinetics and pharmacodynamics of the drug “Ivermectin.”44 Theoretically, the synergistic
effect of this simultaneous inhibition of CYP and P-gp has been
proposed to increase penetration of the drug into the central
nervous system and facilitate interaction with the GABA
receptors.44
The superimposition of the structure and contact map of 10
models of flexibility simulation of human P-gp is shown in
Figures 1 and 2, respectively. Biochemical evidence seems to
favor the idea that the 2 nucleotide-binding domains (NBDs)
are likely in a “constant contact” mode.45,46 Eight major regions
which have been identified on the human P-gp are 1 to 51
(region 1), 73 to 119 (region 2), 141 to 188 (region 3), 237 to
296 (region 4), 347 to 710 (region 5) containing the NBD1,
778 to 832 (region 6), 885 to 936 (region 7), and 995 to 1280
(region 8) containing the NBD2, and others are non-membrane regions, 210 to 215, 318 to 325, 732 to 756, and 958 to
973.47 The RMSF in Armstrong (Å) amino acid residues of
human P-gp shown in Figure 3 shows that regions 1, 2, 3, and
6 are relatively stable within the range of 0 to 1.0 Å, whereas
the fluctuations observed in regions 4, 5, 7, 8, and other nonmembrane regions could account for conformational changes
which facilitate the open and close motions in transport function of P-gp. Esser et al48 have found that the open-and-close
motion of P-gp is structurally linked to conformational changes
of each individual helix of P-gp, and it allows P-gp to change
its surface topology within the drug binding pocket. Previous
molecular dynamics simulation study of human P-gp has

105.2

Total polar surface area (Å 2)

No

No

CYP2C19

Blood–brain barrier (BBB)
permeant

P-glycoprotein substrate

Cytochrome P450 inhibitor

0.55

0.55

–4.38

CYP2C9, CYP2C19,
CYP2D6

No

No

High

Moderately soluble

4.25

113.29

112.16

414.53

B

0.55

–10.04

–

No

No

High

Highly
soluble

–0.13

118.72

73.82

294.3

C

0.55

–2.73

CYP1A2

No

Yes

High

Moderately
soluble

5.42

20.23

80.19

242.44

D

–

0.55

–6.25

Yes

Yes

Low

Soluble

2.45

0

104.75

364.45

E

0.55

–4.5

CYP3A4

No

Yes

High

Soluble

4.79

52.6

91.21

314.46

F

–

0.55

–5.36

Yes

No

Low

Moderately
soluble

1.85

118.18

109.51

444.56

G

0.17

–11.37

–

Yes

No

Low

Highly
soluble

–4.06

198.76

71.17

360.31

H

–

0.55

–5.15

Yes

Yes

High

Soluble

–0.11

40.13

40.4

166.19

I

–

0.17

–6.66

No

No

Low

Moderately
soluble

2.84

195.6

154.81

608.76

J

0.55

–2.82

CYP3A4

No

No

Low

Poorly
soluble

6.99

78.9

135.76

470.68

K

Selected excipients: (A) acetyltributyl citrate, (B) ascorbyl palmitate, (C) aspartame, (D) cetyl alcohol, (E) cetyltrimethyl-ammonium bromide (CTAB), (F) dibutyl sebacate, (G) docusate sodium, (H) lactose monohydrate, (I)
sodium caprylate, (J) sucrose stearate, and (K) tricaprylin (caprylic acid triglyceride).

Bioavailability score

–6.42

High

Gastrointestinal absorption

Skin permeation
Log Kp (cm/s)

Soluble

ESOL class

3.47

103.43

Molar refractivity

Consensus LogP

402.48

A

Selected small molecule excipients

Molecular weight

Parameters

Table 3. Predicted pharmacokinetics parameters of selected first-pass enzymes.
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Table 4. Top medications that contain each of the selected excipients used in this study.
Excipients

Examples of medications

Acetyltributyl citrate

Budesonide (Enteric Coated), Cardizem CD, Dexmethylphenidate Hydrochloride Extended-Release,
Diltiazem Hydrochloride Extended-Release, Glipizide Extended Release, Mesalamine DelayedRelease, Metoprolol Succinate Extended-Release, Potassium Chloride Extended-Release, etc.

Ascorbyl palmitate

Animi-3 with Vitamin D, Enjuvia synthetic B, Integra Vitamin B Complex with C and Iron, Prenatal Plus
Prenatal Vitamin with Iron Fumarate, Tretinoin, Tylenol Regular Strength, Udamin SP dietary
supplement, etc.

Aspartame

Aripiprazole (Orally Disintegrating), Cetirizine Hydrochloride (Chewable), Clonazepam, Lamotrigine
(Orally Disintegrating), Methylphenidate Hydrochloride (Chewable), Mirtazapine (Orally Disintegrating),
Olanzapine (Orally Disintegrating), Ondansetron Hydrochloride (Orally Disintegrating), Risperidone
(Orally Disintegrating), Rizatriptan Benzoate (Orally Disintegrating), Zolmitriptan (Orally Disintegrating)

Cetyl alcohol

Amoxicillin and Clavulanate Potassium, Budesonide, Dextroamphetamine Sulfate Extended Release,
Lansoprazole Delayed Release (Orally Disintegrating), Methylphenidate Hydrochloride ExtendedRelease, Omeprazole Delayed Release, Ursodiol, etc.

Dibutyl sebacate

Bupropion Hydrochloride Extended-Release (XL), Methylphenidate Hydrochloride ExtendedRelease, Omeprazole Delayed Release, Potassium Chloride Extended-Release, Propranolol
Hydrochloride Extended-Release, Tramadol Hydrochloride Extended Release, Venlafaxine
Hydrochloride Extended Release, Verapamil Hydrochloride Extended-Release, etc.

Docusate sodium

Euro-Docusate, Docusate-Humanity, Otitex, Glyoktyl, Vencoll, Humectol-D, etc.

Lactose monohydrate

Acetaminophen and Oxycodone Hydrochloride, Alprazolam, Cetirizine Hydrochloride, Clonazepam,
Cyclobenzaprine Hydrochloride, Oxycodone Hydrochloride, Tramadol Hydrochloride, etc.

Sucrose stearate

ConZip, Diltiazem Hydrochloride Extended-Release, Esomeprazole Magnesium Delayed-Release,
Prasugrel Hydrochloride, Tiazac, Tramadol Hydrochloride Extended Release, etc.

Cetyltrimethyl-ammonium
bromide (CTAB)

Aflunov, Foclivia, Xylonor, Savlodil, and other topical antiseptic cetrimide, shampoos, and cosmetics
(ref. https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3567)

Tricaprylin and sodium
caprylate

There is no validated scientific data to support the use of caprylic acid and its derivatives as sole
medicine for any health problem (ref. https://www.drugs.com/npc/caprylic-acid.html).

Bolded medications contained more than one of the excipients investigated in this study.

Figure 1. Superimposition of top 10 simulated structures of human P-glycoprotein obtained from CAB-flex 2.0 server.
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consultation has been made to increase access to ingredient
information online to assure therapeutic goods administration
to the consumers.54 Many potential drugs might have been discarded as a result of limited efficacy due to unsuitable excipients. Specific cases of variation in 2 excipients (mannitol or
trehalose, and metoprolol or sorbitol), leading to counteraction
of the activity of the active agent have been reported.55,56
Comprehensive review on the potential for excipients to alter
the individual response to or tolerance of a medication brand
has been published recently by Page and Etherton-Beer,57
which could affect pediatric and adult populations with different toxicological outcomes.58,59 Thus, excipients bioavailability,
API-excipient, and excipient–excipient interactions should be
investigated during drug formulation, as this could be the basis
of specific side effects.

Conclusions
Figure 2. Contact map of superimposition of top 10 simulated structures
of human P-glycoprotein obtained from CAB-flex 2.0 server.

This study showed that some excipients can change drug
metabolism through the effects on cytochrome P450 activity
and P-gp function. The presence of some excipients in drug
formulation for oral administration in single or multiple
drugs prescription in the presence or absence of gastrointestinal food contents may lead to pharmacokinetic interactions
and possibly reduce efficacy on the pathogen or host organism molecular targets, which are relevant to microbial drug
resistance and toxicity in pediatric and adult populations.
Hence, the clinical significance of findings from this in silico
work should be taken into consideration during drug formulation and administration.

Author Contributions

Authors THF, OI, and OAA designed the study, while THF
conducted the analyses. All authors were involved in the interpretation of the results, preparation and revision of the manuscript, and approved the final version of the manuscript.
Figure 3. Root-mean square fluctuations (unit in Å) of amino acid
residues in the human P-glycoprotein obtained from CAB-flex 2.0 server.

shown that residues D177 and N820 interact with tariquidar
when the NBDs were in the closed positions in these simulations, and that this interaction may be essential in its mechanism of inhibition.49 There is strong evidence that tariquidar
has a much higher affinity to P-gp and slower off-rate from
P-gp than vinblastine, a good transport substrate.50 A study has
shown small RMSD changes of 1 to 2.5 Å for a series of P-gp
transport substrates.51
The therapeutic efficacy of API must be balanced by the
functionality of the excipients to assure the quality and safety
of the drug.52 The safety-toxicity assessments are classically
based on the appearance of gross morphological changes rather
than the effects on a cellular level, whereas the ability of excipients in modifying the pharmacological activity by modulating
transporters of an active drug which could lead to toxicity
should be rational approach of assessment.53 In Australia,
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